I'm actually thinking of suing CGM. After the August 2015 collapse I convinced my wife we should get her 403B out of Focus and Realty. At the end of Sept she contacted them to roll it into a traditional IRA at Schwab and was told this was not possible. She asked if they could move her money into a money market or balanced fund that might be more risk appropriate for someone a couple of years from retirement and was told that the Fund manager did not want to offer such funds because he thought it would encourage market timing and he did not want to deal with funds sloshing between funds.
They have to realize that people have other reasons for wanting to mitigate risks other than market timing. Looking for an attorney!
Was it Fed speak from Dudley or the ISM being lower than anticipated? Anything commodity related shot up when the dollar weakened after the ISM data release.
If you looks at the path Onco DX Breast took you can see this this downgrade is BS, probably meant to create a buying opportunity.
Piper Jaffray downgraded Genomic Health Inc. (NASDAQ: GHDX) from Overweight to Neutral with a price target of $32.00 (from $36.00) as they shift their focus to 2017.
Analyst William Quirk commented: "We are downgrading Genomic Health on a contrarian call as we look beyond the 2016 reacceleration to 2017 expectations. We believe revenue growth in 2017 will slow from 2016 as Prostate and OUS face tougher comps. Specifically, we believe private payer reimbursement will be limited as we remain cautious on the test's ability to predict disease recurrence. With NICE and German ODX Breast reimbursement also comping in 2017, we anticipate it will be incrementally challenging to drive accelerated growth above 2016 levels. Finally, the stock is up 43% since the recent bottom and is trading above the peer group (2.6x FY17E EV/rev vs. peers median of 1.7x) despite ~10.1% growth in 2017 (peer median is ~38% 2017 growth). Accordingly, we believe shares are fairly valued and are downgrading to a Neutral from Overweight. Our price target is now $32 (was $36) based on 2.5x FY17E EV/Rev (was 2.75x)."The firm cut FY 2016 EPS from $0.10 to $0.00 and FY 2017 EPS from $0.31 to $0.29.
For an analyst ratings summary and ratings history on Genomic Health Inc. click here. For more ratings news on Genomic Health Inc. click here.
Shares of Genomic Health Inc. closed at $31.66 yesterday.
Not a big jump to extrapolate the cruise industry warnings to the airlines.
Market getting wacked again today. Ray Dalio was on CNBC discussing how we are in a typical debt cycle. As I have mentioned before, GHDX makes sense in this environment since they are selling into over leveraged debt carrying developed markets with older populations. These governments are desperate to reign in health care spending costs. GHDX is offering tools to make these expenditures more efficiently and hopefully save money by avoiding expensive over treatment. While GHDX may take a hit in the short term as the overall markets decline, the low float will make it hard for big institutional buyers to establish positions without driving prices up. Therefore, there are huge risks trying to trade in and out of GHDX.
I believe the same. They have had a D rating on my best performing equity GHDX . I think they totally disregard fundamental issues like new products and increasing rev growth etc.
I tend to disagree. The uptrend at the end of December correlates almost to the day that GHDX was included into the IBB. There has been a pronounced increase in volume ever since.
That said liquid biopsy is in the news and is garnering appreciable excitement. Witness the Grail news yesterday. GHDX is not looking for the proteins that are markers of an existing cancer as Grail claims to be. Rather it appears that GHDX is going to provide a genomic profile to identify potential susceptibility to cancer and also (probably more importantly) provide a pathway as to which treatment pathway is likely to be most effective.
I believe this is GHDX's strong suit. They are focused on providing actionable data.
2016 could well be a challenging year do to macro conditions. However, as I've indicated before. companies that result in health care cost savings (by aiding in selection of the best treatment options) are likely to be in a sweet spot.
Given the positive liquid biopsy news, it looks like the market is using the overall weakness in biotech this morning to try to shake out some weak hands in GHDX. Probably better not to watch day to day action too closely.
Got stopped out last week. I entered zbra as a trade thinking it was in a channel and would trade up to 75. It never made it. I will look to get back in when the selling pressure subsides. The tape is too ugly right now to go against the grain. I'll be listening to the call to see about new product uptake and the paydown of debt.
My investing thesis is to target companies that bring efficiencies and cost savings to their clients and/or payors. So far I've done well with GHDX . It has a two gene tests (Breast and prostate cancer) that really help physicians determine the best course of treatment.
While GHDX saw a nice runup a couple weeks ago when they were added to the IBB, I think we saw the opposite effect yesterday. The late day sell-off on high volume had all the earmarks of being associated with ETF's selling off tom meet redemption requests.
Either way it looks like GHDX is moving into a new growth phase just when the wheels look to be coming off the market as a whole. I thought of selling some of my position a couple days ago since I thought the downdraft could spread to GHDX. I decided against this for the following reason. The news flow is likely to start improving appreciably this quarter. With the limited float re-entry into GHDX at a later date could be expensive. We are seeing upgrades with higher target prices. The guidance that they will more than triple revenue in the next four years suggests growth in the 20%+ range. I believe we are headed into a time when growth will be hard to come by. Finally, governments across the world are in serious debt and many are facing a rapidly aging demographic population with maladies such as cancer taking a bigger bite out of their health care appropriations. How will these governments manage to both take care of their aging populations and control their budgets? By spending much more efficiently. This means limiting over spending. GHDX is ideally situated at this crossroads.
For these reasons, I've decided to hold despite the impending market turmoil.
Yeah something fundamental has changed, Americans are keeping their vehicles longer than ever before. I just heard on WBBM in Chicago that the average car on the road is now 13 years old. This represents the longest that Americans have ever kept their vehicles. One has to believe that at some point the costs of upkeep will spur the purchase of new cars. This is just another example of how 2008-2009 scared the psych of the consumer. Some millennials are clearly part of the sharing economy and not purchase vehicles of their own anytime soon. However, I believe this will change with time.
$44 target! More interesting is that they performed a survey of urologists that indicates the Onco DX prostate test has better visibility than the MYGN Prolaris test.
I had thought of reducing my position at the end of 2015 in anticipation of overall market downdraft (nothing specific to GHDX). However, I decided that the growth over the next 4 or 5 years would make such a move too risky. The float is simply too low to risk jumping in and out.
After 4 years there has not been much in the way of premium increases on the 10Pay. I think most of the premium increases hit policies that did not have capped benefits. Our policy has a capped benefit that would limit GNW's long term exposure. The chief risk to GNW is that the policy has a 5% annual inflation increase. In the current environment it may be difficult for them to find suitable investments.
I'm about half way thru 10 Pay LTC payments (purchased thru AARP) and dread this time of year. For the past two years I've watched while GNW share price decreased and while the rating agencies issue multiple downgrades. Financial advisers (not the same ones that sold the policy) say to keep making the payments but it is concerning to see GNW the largest LTC insurance provider struggling. From what I can see, the policy is backstopped by an insurance fund managed by the state where my wife and I live -ILLINOIS-. Now that makes me feel alot better.
Given the inability of private insures to adequately manage the risks of this insurance line, what are the chances that Medicaid (the largest and last resort for many Americans) will be able to withstand the financial burden when the Baby Boomers hit peak nursing home years (maybe 15-20 yrs from now)?
Hoping this thing gets turned around!
As a Geologist I'm always amazed to the degree that psychological factors dictate PM prices. You'd think that logic (i.e., % relative abundance in the earths crust, multitude of uses, industrial, jewelry etc.) would dictate value rather than arbitrary age old axiom that gold is the best store of wealth.